LSE:AZNPharmaceuticals
Is AstraZeneca Still Attractive After Strong 2025 Rally and Pipeline Driven Revaluation?
Wondering if AstraZeneca is still a smart buy after its big run, or if you are late to the party? This breakdown will help you decide whether the current price really matches the long term story.
The stock has slipped about 3.6% over the last week but is still up 7.9% over the past month, 27.1% year to date, and roughly 30.0% over the last year, suggesting strong momentum with a bit of recent cooling.
Recently, AstraZeneca has stayed in the spotlight with a steady stream of pipeline updates...